A first‐in‐human, single and multiple dose study of lunsekimig, a novel anti‐TSLP/anti‐IL‐13 NANOBODY® compound, in healthy volunteers

• Үндсэн зохиолчид: Annemie Deiteren (Зохиогч), Lieselot Bontinck (Зохиогч), Griet Conickx (Зохиогч), Marie Vigan (Зохиогч), Nele Dervaux (Зохиогч), Matthieu Gassiot (Зохиогч), Selcuk Bas (Зохиогч), Benjamin Suratt (Зохиогч), Heribert Staudinger (Зохиогч), Emmanuel Krupka (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Wiley, 2024-06-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Lunsekimig is a novel, bispecific NANOBODY® molecule that inhibits both thymic stromal lymphopoietin (TSLP) and interleukin (IL)‐13, two key mediators of asthma pathophysiology. In this first‐in‐human study, we evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD)...